Nonalcoholic Fatty Liver Disease and the Gut Microbiome

Clinics in Liver Disease

Volumn 20, Issue 2, 2016, Pages 263-275

  Boursier, Jerome ^a,b   Diehl, Anna Mae ^c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b SFR 4208 LUNAM University   (France)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fatty liver; Fibrosis; Gut microbiota; Hepatocellular carcinoma; Liver cirrhosis; Nonalcoholic fatty liver disease; Steatohepatitis

Indexed keywords

BILE ACID; PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID; TOLL LIKE RECEPTOR 4;

ACIDAMINOCOCCACEAE; ALPHAPROTEOBACTERIA; BACILLI; BACTERIAL OVERGROWTH; BACTEROIDETES; CLOSTRIDIA; CLOSTRIDIALES; CLOSTRIDIUM; DISEASE SEVERITY; DYSBIOSIS; ENDOTOXEMIA; ENTEROBACTERIACEAE; ESCHERICHIA; FAECALIBACTERIUM PRAUSNITZII; FATTY LIVER; FIRMICUTES; GAMMAPROTEOBACTERIA; HEPATITIS; HUMAN; INTESTINE FLORA; LACHNOSPIRACEAE; LACTOBACILLACEAE; LACTOBACILLALES; LACTOBACILLUS; LIPID DIET; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER METABOLISM; METABOLOMICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PASTEURELLACEAE; PASTEURELLALES; PORPHYROMONADACEAE; PROTEOBACTERIA; REVIEW; RUMINOCOCCACEAE; SMALL INTESTINAL BACTERIAL OVERGROWTH; ANIMAL; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; CARCINOMA, HEPATOCELLULAR; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84951843544     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2015.10.012     Document Type: Review

References (64)

1. Gill S.R., Pop M., Deboy R.T., et al. Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355-1359.
2. Backhed F., Ley R.E., Sonnenburg J.L., et al. Host-bacterial mutualism in the human intestine. Science 2005, 307:1915-1920.
3. Turnbaugh P.J., Hamady M., Yatsunenko T., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
4. Cerf-Bensussan N., Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes?. Nat Rev Immunol 2010, 10:735-744.
5. Nicholson J.K., Holmes E., Kinross J., et al. Host-gut microbiota metabolic interactions. Science 2012, 336:1262-1267.
6. Janssen A.W., Kersten S. The role of the gut microbiota in metabolic health. FASEB J 2015, 29(8):3111-3123.
7. Wiest R., Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005, 41:422-433.
8. Weinstock G.M. Genomic approaches to studying the human microbiota. Nature 2012, 489:250-256.
9. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012, 142:711-725.e6.
10. Angulo P., Kleiner D.E., Dam-Larsen S., et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015, 149(2):389-397.e10.
11. Ekstedt M., Hagstrom H., Nasr P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015, 61:1547-1554.
12. Younossi Z.M., Stepanova M., Afendy M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011, 9:524-530.
13. Le Roy T., Llopis M., Lepage P., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013, 62:1787-1794.
14. Newgard C.B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012, 15:606-614.
15. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
16. Sajjad A., Mottershead M., Syn W.K., et al. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005, 22:291-299.
17. Sabate J.M., Jouet P., Harnois F., et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008, 18:371-377.
18. Miele L., Valenza V., La Torre G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
19. Shanab A.A., Scully P., Crosbie O., et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011, 56:1524-1534.
20. Caricilli A.M., Saad M.J. The role of gut microbiota on insulin resistance. Nutrients 2013, 5:829-851.
21. Volynets V., Kuper M.A., Strahl S., et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2012, 57:1932-1941.
22. Backhed F., Ding H., Wang T., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101:15718-15723.
23. Backhed F., Manchester J.K., Semenkovich C.F., et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007, 104:979-984.
24. Jiang C., Xie C., Li F., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015, 125:386-402.
25. den Besten G., van Eunen K., Groen A.K., et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013, 54:2325-2340.
26. Zhu L., Baker R.D., Baker S.S. Gut microbiome and non-alcoholic fatty liver diseases. Pediatr Res 2015, 77(1-2):245-251.
27. Puertollano E., Kolida S., Yaqoob P. Biological significance of short-chain fatty acid metabolism by the intestinal microbiome. Curr Opin Clin Nutr Metab Care 2014, 17:139-144.
28. Vrieze A., Van Nood E., Holleman F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916.e7.
29. Maher J.J. New insights from rodent models of fatty liver disease. Antioxid Redox Signal 2011, 15:535-550.
30. Craciun S., Balskus E.P. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci U S A 2012, 109:21307-21312.
31. Dumas M.E., Barton R.H., Toye A., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006, 103:12511-12516.
32. Spencer M.D., Hamp T.J., Reid R.W., et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011, 140:976-986.
33. Lassailly G., Caiazzo R., Buob D., et al. Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015, 149(2):379-388.
34. Liou A.P., Paziuk M., Luevano J.M., et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013, 5:178ra141.
35. Raman M., Ahmed I., Gillevet P.M., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013, 11:868-875.e1-3.
36. Mouzaki M., Comelli E.M., Arendt B.M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58:120-127.
37. Zhu L., Baker S.S., Gill C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57:601-609.
38. Wong V.W., Tse C.H., Lam T.T., et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-a longitudinal study. PLoS One 2013, 8:e62885.
39. Munukka E., Pekkala S., Wiklund P., et al. Gut-adipose tissue axis in hepatic fat accumulation in humans. J Hepatol 2014, 61:132-138.
40. Schnabl B., Brenner D.A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014, 146:1513-1524.
41. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
42. Farhadi A., Gundlapalli S., Shaikh M., et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008, 28:1026-1033.
43. Ruiz A.G., Casafont F., Crespo J., et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007, 17:1374-1380.
44. Alisi A., Manco M., Devito R., et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010, 50:645-649.
45. Yuan J., Baker S.S., Liu W., et al. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2014, 29:1292-1298.
46. De Minicis S., Rychlicki C., Agostinelli L., et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury. Hepatology 2014, 59:1738-1749.
47. Zhu Q., Zou L., Jagavelu K., et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol 2012, 56:893-899.
48. Yoshimoto S., Loo T.M., Atarashi K., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
49. Calkin A.C., Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 2012, 13:213-224.
50. Chiang J.Y. Bile acid metabolism and signaling. Compr Physiol 2013, 3:1191-1212.
51. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385:956-965.
52. David L.A., Maurice C.F., Carmody R.N., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505:559-563.
53. de Wit N.J., Afman L.A., Mensink M., et al. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol 2012, 57:1370-1373.
54. Spruss A., Kanuri G., Wagnerberger S., et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50:1094-1104.
55. Kanuri G., Spruss A., Wagnerberger S., et al. Role of tumor necrosis factor alpha (TNFalpha) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2011, 22:527-534.
56. Bergheim I., Weber S., Vos M., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008, 48:983-992.
57. Abenavoli L., Scarpellini E., Rouabhia S., et al. Probiotics in non-alcoholic fatty liver disease: which and when. Ann Hepatol 2013, 12:357-363.
58. Parnell J.A., Raman M., Rioux K.P., et al. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int 2012, 32:701-711.
59. Okubo H., Sakoda H., Kushiyama A., et al. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol 2013, 305:G911-G918.
60. Anhe F.F., Roy D., Pilon G., et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 2015, 64:872-883.
61. Ferolla S.M., Armiliato G.N., Couto C.A., et al. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients 2014, 6:5583-5599.
62. Tarantino G., Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol 2015, 10:889-902.
63. Ma Y.Y., Li L., Yu C.H., et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013, 19:6911-6918.
64. Alisi A., Bedogni G., Baviera G., et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014, 39:1276-1285.